AT323181B - Verfahren zur herstellung von neuen pyrrolo (3,4-b) pyrazinderivaten sowie von deren säureadditionssalzen - Google Patents

Verfahren zur herstellung von neuen pyrrolo (3,4-b) pyrazinderivaten sowie von deren säureadditionssalzen

Info

Publication number
AT323181B
AT323181B AT10073A AT10073A AT323181B AT 323181 B AT323181 B AT 323181B AT 10073 A AT10073 A AT 10073A AT 10073 A AT10073 A AT 10073A AT 323181 B AT323181 B AT 323181B
Authority
AT
Austria
Prior art keywords
preparation
acid addition
addition salts
pyrazine derivatives
new pyrrolo
Prior art date
Application number
AT10073A
Other languages
German (de)
English (en)
Original Assignee
Rhone Poulenc Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR7200505A external-priority patent/FR2166314A1/fr
Priority claimed from FR7239731A external-priority patent/FR2205318A2/fr
Application filed by Rhone Poulenc Sa filed Critical Rhone Poulenc Sa
Application granted granted Critical
Publication of AT323181B publication Critical patent/AT323181B/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT10073A 1972-01-07 1973-01-05 Verfahren zur herstellung von neuen pyrrolo (3,4-b) pyrazinderivaten sowie von deren säureadditionssalzen AT323181B (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR7200505A FR2166314A1 (en) 1972-01-07 1972-01-07 6-substd 5-(4-methyl 1-piperazinyl)carbonyloxy 7-oxo - 5,6-dihydro-pyrrolo (3,4-b)pyrazines - tranquillizers and anticonvuls
FR7239731A FR2205318A2 (en) 1972-11-09 1972-11-09 6-substd 5-(4-methyl 1-piperazinyl)carbonyloxy 7-oxo - 5,6-dihydro-pyrrolo (3,4-b)pyrazines - tranquillizers and anticonvuls

Publications (1)

Publication Number Publication Date
AT323181B true AT323181B (de) 1975-06-25

Family

ID=26216824

Family Applications (1)

Application Number Title Priority Date Filing Date
AT10073A AT323181B (de) 1972-01-07 1973-01-05 Verfahren zur herstellung von neuen pyrrolo (3,4-b) pyrazinderivaten sowie von deren säureadditionssalzen

Country Status (22)

Country Link
US (1) US3862149A (OSRAM)
JP (3) JPS523952B2 (OSRAM)
AR (1) AR195097A1 (OSRAM)
AT (1) AT323181B (OSRAM)
AU (1) AU466586B2 (OSRAM)
BE (1) BE793730A (OSRAM)
CA (1) CA991183A (OSRAM)
CY (1) CY915A (OSRAM)
DD (1) DD102698A5 (OSRAM)
DE (1) DE2300491C3 (OSRAM)
DK (1) DK139359B (OSRAM)
FI (1) FI54124C (OSRAM)
GB (1) GB1358680A (OSRAM)
HK (1) HK60077A (OSRAM)
HU (1) HU164821B (OSRAM)
IE (1) IE37056B1 (OSRAM)
IL (1) IL41232A (OSRAM)
LU (1) LU66800A1 (OSRAM)
NL (1) NL7217852A (OSRAM)
NO (1) NO136843C (OSRAM)
OA (1) OA04285A (OSRAM)
SE (1) SE398503B (OSRAM)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2322601A1 (fr) * 1975-09-04 1977-04-01 Rhone Poulenc Ind Nouveaux derives de l'isoindoline, leur preparation et les compositions qui les contiennent
AR208414A1 (es) * 1974-11-07 1976-12-27 Rhone Poulenc Ind Procedimiento para obtener nuevos derivados de la((acil-4piperazinil-1)carboniloxi-5 pirrolinona-2)
US4590189A (en) * 1982-04-02 1986-05-20 Takeda Chemical Industries, Ltd. Condensed pyrrolinone derivatives, their production and use
JPS6169773A (ja) * 1984-09-14 1986-04-10 Takeda Chem Ind Ltd イソインドリノン誘導体
JPS6297400U (OSRAM) * 1985-12-09 1987-06-20
FR2607504B1 (fr) * 1986-12-02 1989-01-27 Rhone Poulenc Sante Nouveaux derives de l'isoindolinone, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2671800B1 (fr) * 1991-01-17 1993-03-12 Rhone Poulenc Rorer Sa Derive de la 5h-pyrrolo[3,4-b]pyrazine optiquement actif, sa preparation et les compositions pharmaceutiques qui le contiennent.
AU3275993A (en) * 1991-12-02 1993-06-28 Sepracor, Inc. Methods and compositions for treating sleep disorders, convulsive seizures, and other disorders using optically pure (-) zopiclone
US5786357A (en) 1991-12-02 1998-07-28 Sepracor Inc. Methods and compositions for treating sleep disorders, convulsive seizures and other disorders using optically pure (+) zopiclone
AU3245593A (en) * 1991-12-02 1993-06-28 Sepracor, Inc. Methods and compositions for treating sleep disorders, convulsive seizures, and other disorders using optically pure (+) zopiclone
US6348485B1 (en) 1998-06-09 2002-02-19 Takeda Chemical Industries, Ltd. Method for treating or preventing sleep disorders
US6339086B1 (en) * 1999-05-14 2002-01-15 Swpracor, Inc. Methods of making and using N-desmethylzopiclone
ES2203319B1 (es) * 2002-04-03 2005-03-01 Universidad De Oviedo Nuevos carbonatos opticamente activos como intermedios en la sintesis de (+)-zopiclona.
US20050176680A1 (en) 2003-12-11 2005-08-11 Sepracor, Inc. Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
CA2614209A1 (en) * 2005-07-06 2007-01-11 Sepracor Inc. Combinations of eszopiclone and o-desmethylvenlafaxine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
AU2006264317B2 (en) 2005-07-06 2012-02-23 Sunovion Pharmaceuticals Inc. Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
US7476737B2 (en) * 2005-09-05 2009-01-13 Dr. Reddy's Laboratories Limited Eszopiclone process
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
EP1984371A1 (en) * 2006-02-03 2008-10-29 Synthon B.V. Zopiclone resolution using l-tartaric acid
US20100216734A1 (en) * 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP1991212A1 (en) * 2006-03-08 2008-11-19 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007109799A2 (en) * 2006-03-23 2007-09-27 Teva Pharmaceutical Industries Ltd. Polymorphs of eszopiclone malate
WO2007124025A2 (en) * 2006-04-20 2007-11-01 Teva Pharmaceutical Industries Ltd. Methods for preparing eszopiclone crystalline form a, substantially pure eszopiclone and optically enriched eszopiclone
CN101058581B (zh) * 2006-04-21 2011-06-08 天津天士力集团有限公司 右佐匹克隆中间体6-(5-氯-2-吡啶基)-5,7-二氧代-6,7-二氢-5H-吡咯并[3,4-b]吡嗪的制备方法
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
CA2651862A1 (en) * 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
US20080015197A1 (en) * 2006-06-26 2008-01-17 Alex Mainfeld Process for the preparatrion of zopiclone
KR20090064418A (ko) * 2006-09-08 2009-06-18 브레인셀즈 인코퍼레이션 4-아실아미노피리딘 유도체 포함 조합물
US20080103165A1 (en) * 2006-09-19 2008-05-01 Braincells, Inc. Ppar mediated modulation of neurogenesis
US7786304B2 (en) * 2006-11-06 2010-08-31 Centaur Pharmaceutical Pvt. Ltd. Process for the preparation of eszopiclone
WO2008094690A2 (en) * 2007-01-31 2008-08-07 Teva Pharmaceutical Industries Ltd. Methods for preparing eszopiclone
US20080305171A1 (en) * 2007-06-07 2008-12-11 Kristin Anne Arnold Pyrrolopyrazine, formulations, methods of manufacture, and methods of use there
US20090018336A1 (en) * 2007-06-25 2009-01-15 Nina Finkelstein Racemization process of R-zopiclone
EP2020403A1 (en) 2007-08-02 2009-02-04 Esteve Quimica, S.A. Process for the resolution of zopiclone and intermediate compounds
WO2009063486A2 (en) * 2007-08-06 2009-05-22 Usv Limited Process for preparation of dextrorotatory isomer of 6-(5-chloro-pyrid-2-yi)-5-[(4-methyl -1-piperazinyl) carbonyloxy]-7-oxo-6,7-dihydro-5h-pyrrolo [3,4-b] pyrazine (eszopiclone)
JP2011506427A (ja) * 2007-12-11 2011-03-03 シプラ・リミテッド ゾピクロンおよびその多形相の新規製造方法
US8198278B2 (en) * 2007-12-19 2012-06-12 Sunovion Pharmaceuticals Inc. Besylate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US8212036B2 (en) 2007-12-19 2012-07-03 Sunovion Pharmaceuticals Inc. Maleate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
CA2747000C (en) * 2007-12-19 2013-09-03 Sunovion Pharmaceuticals Inc. Maleate, besylate, and l-malate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5h-pyrrolo[3,4-b]pyrazine
US8268832B2 (en) * 2007-12-19 2012-09-18 Sunovion Pharmaceuticals Inc. Maleate salts of 6-(5-chloro-2-Pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US8198277B2 (en) * 2007-12-19 2012-06-12 Sunovion Pharmaceuticals Inc. L-malate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US8269005B2 (en) * 2007-12-19 2012-09-18 Sunovion Pharmaceuticals Inc. L-malate salts of 6-(5-chloro-2-Pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-Oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
WO2009085988A1 (en) * 2007-12-19 2009-07-09 Sepracor Inc. Salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7- dihydro-5h-pyrrolo[3,4-b]pyrazine
CN100467471C (zh) * 2007-12-19 2009-03-11 齐鲁天和惠世制药有限公司 佐匹克隆的制备方法
JP2012516348A (ja) 2009-01-30 2012-07-19 サノビオン ファーマシューティカルズ インク ６−（５−クロロ−２−ピリジル）−５−［（４−メチル−１−ピペラジニル）カルボニルオキシ］−７−オキソ−６，７−ジヒドロ−５Ｈ−ピロロ［３，４−ｂ］ピラジンの被覆錠剤及びコーティングの効果を測定する方法
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CN105399745A (zh) * 2015-12-17 2016-03-16 天津华津制药有限公司 一种吡嗪并羟基吡咯烷酮类化合物的制备方法
EP3468545A4 (en) 2016-06-08 2020-07-22 President and Fellows of Harvard College METHODS AND COMPOSITIONS FOR REDUCING TACTILE DYSFUNCTION AND ANXIETY ASSOCIATED WITH AUTISM SPECTRUM DISORDER, RETT SYNDROME AND FRAGILE X SYNDROME
CN106220630B (zh) * 2016-07-23 2019-12-10 迪嘉药业集团有限公司 一种n-取代吡咯并[3,4-b]吡嗪-5,7(6h)-二酮的制备方法
EP3797097A4 (en) 2018-05-22 2022-03-09 President and Fellows of Harvard College Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment
EP3801512A4 (en) 2018-05-29 2022-01-19 President and Fellows of Harvard College COMPOSITIONS AND METHODS FOR REDUCING TOUCH DYSFUNCTION, ANXIETY AND SOCIAL DISABILITY
EP3946390A4 (en) 2019-03-25 2022-12-21 President and Fellows of Harvard College COMPOSITIONS AND METHODS TO REDUCE TACTILE DYSFUNCTION, ANXIETY AND SOCIAL DISABILITIES
CN114437027A (zh) * 2021-12-22 2022-05-06 深圳市祥根生物医药有限公司 一种佐匹克隆n-氧化杂质的制备方法

Also Published As

Publication number Publication date
AR195097A1 (es) 1973-09-10
SE398503B (sv) 1977-12-27
IL41232A (en) 1975-12-31
DE2300491A1 (de) 1973-07-19
JPS535315B2 (OSRAM) 1978-02-25
NO136843C (no) 1977-11-16
FI54124C (fi) 1978-10-10
IE37056L (en) 1973-07-07
JPS5231358B2 (OSRAM) 1977-08-13
NO136843B (no) 1977-08-08
JPS5248687A (en) 1977-04-18
NL7217852A (OSRAM) 1973-07-10
HK60077A (en) 1977-12-09
HU164821B (OSRAM) 1974-04-11
AU5075473A (en) 1974-07-04
OA04285A (fr) 1979-12-31
BE793730A (fr) 1973-07-05
AU466586B2 (en) 1975-10-30
JPS4876892A (OSRAM) 1973-10-16
DE2300491C3 (de) 1978-05-18
FI54124B (fi) 1978-06-30
CY915A (en) 1977-12-23
DE2300491B2 (de) 1977-09-08
LU66800A1 (OSRAM) 1973-07-18
CA991183A (fr) 1976-06-15
DK139359C (OSRAM) 1979-07-09
US3862149A (en) 1975-01-21
JPS523952B2 (OSRAM) 1977-01-31
IE37056B1 (en) 1977-04-27
IL41232A0 (en) 1973-03-30
GB1358680A (en) 1974-07-03
DD102698A5 (OSRAM) 1973-12-20
DK139359B (da) 1979-02-05
JPS5248688A (en) 1977-04-18

Similar Documents

Publication Publication Date Title
AT323181B (de) Verfahren zur herstellung von neuen pyrrolo (3,4-b) pyrazinderivaten sowie von deren säureadditionssalzen
AT327919B (de) Verfahren zur herstellung von neuen benzodiazepinderivaten und deren saureadditionssalzen
AT351544B (de) Verfahren zur herstellung von neuen 1,5,10,10a- tetrahydrothiazolo-(3,4-b) -isochinolin-derivaten und von deren saeure- additonssalzen
AT322547B (de) Verfahren zur herstellung von neuen 2-phenylaminoimidazolin-(2)-derivaten und deren säureadditionssalzen
AT332873B (de) Verfahren zur herstellung neuer imidazo (4,5-b) pyridine und deren saureadditionssalze
AT332863B (de) Verfahren zur herstellung von neuen 2-aminomethyl-4,6-dihalogenphenolderivaten sowie deren additionssalzen mit sauren
AT319252B (de) Verfahren zur Herstellung von neuen Pyrido[3,2-d]pyrimidinen und von deren Säureadditionssalzen
AT336015B (de) Verfahren zur herstellung von neuen aminoderivaten von pyrazolo (3,4-b)pyridinen und deren saureadditionssalzen
AT319956B (de) Verfahren zur Herstellung von neuen Diazepinderivaten, ihrer 5-Oxyde und deren Säureadditionssalzen
AT320611B (de) Verfahren zur Herstellung von neuen substituierten Phenylformamidinen und deren Säureadditionssalzen
AT330789B (de) Verfahren zur herstellung von neuen (1,4) ditihiino (2,3-c) pyrrolderivaten und von deren saureadditionssalzen
AT317898B (de) Verfahren zur Herstellung von neuen 5,6-Dihydro-pyrrolo[3,4-]pyridinderivaten und deren Säureadditionssalzen
ATA163577A (de) Verfahren zur herstellung von neuen 3-aminomethyl-2-phenylbicyclo (2,2,2) octanen und -octenen sowie deren saureadditionssalzen
AT313300B (de) Verfahren zur Herstellung von neuen Guanidinophenylharnstoffderivaten sowie von deren Säureadditionssalzen
AT327202B (de) Verfahren zur herstellung von neuen benzodiazepinderivaten und deren saureadditionssalzen
AT331778B (de) Verfahren zur herstellung von neuen 2,2,3-trimethyl-7-aminonorbornanen und deren saureadditionssalzen
AT351030B (de) Verfahren zur herstellung von neuen 1,2- dihydro-6-phenyl-1h,4h-imidazo (1,2a) (1,4) benzodiazepin-1-onen sowie von deren saeure- additionssalzen
AT352136B (de) Verfahren zur herstellung von neuen 1,5,10,10a- tetrahydrothiazolo-(3,4-b) -isochinolin-derivaten und von deren saeure- additionssalzen
AT309429B (de) Verfahren zur Herstellung von neuen Imidazo[4,5-b]pyridinderivaten sowie von deren Säureadditionssalzen und quarternären Ammoniumderivaten
AT317230B (de) Verfahren zur Herstellung von neuen Diazepinderivaten sowie deren 5-Oxyden und deren Säureadditionssalzen
AT349470B (de) Verfahren zur herstellung von neuen 4,4- diphenylcyclohexylpiperidinderivaten sowie deren pharmazeutisch anwendbaren saeureadditionssalzen
AT353247B (de) Verfahren zur herstellung von neuen 1-amino- oder 1-aminomethyl-7,7-dimethyl-2,2,1-cyclo- heptanen sowie von deren saeureadditionssalzen
AT309434B (de) Verfahren zur herstellung von neuen imidazo (4,5-b)pyridinderivaten sowie von deren saeureadditionssalzen und quaternaeren ammoniumderivaten
AT327165B (de) Verfahren zur herstellung von neuen substituierten 3-chlor-2-hydrazonomethyl-4-aza-2,4-pentadiennitrilen sowie deren saureadditionssalzen
AT330768B (de) Verfahren zur herstellung von neuen 2-phenylaminoimidazolin- (2) -derivaten und deren saureadditionssalzen